IC
PMVP icon

Ikarian Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Ikarian Capital’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Hold
89,136
– – 0.01% 145
2026
Q1 		$111K Hold
89,136
– – 0.01% 147
2025
Q4 		$111K Sell
89,136
-8,364
-9% -$11.2K 0.01% 161
2025
Q3 		$137K Buy
+97,500
New +$135K 0.01% 159

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Ikarian Capital's PMVP Position: Q2 2026 in Review

Ikarian Capital held its PMV Pharmaceuticals (PMVP) position steady in Q2 2026 at 89,136 shares worth $119K. The position accounts for 0.01% of the portfolio, ranked #145.

Ikarian Capital first reported a position in PMVP in Q3 2025 and has held it in 4 quarters since. The position peaked at $137K in Q3 2025. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Ikarian Capital held 89,136 shares of PMV Pharmaceuticals worth $119K as of Q2 2026.
  • Ikarian Capital left its PMV Pharmaceuticals share count unchanged in Q2 2026.
  • PMV Pharmaceuticals made up 0.01% of Ikarian Capital's portfolio in Q2 2026, its #145 holding.
  • Ikarian Capital first reported a position in PMV Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Ikarian Capital's PMV Pharmaceuticals position peaked at $137K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.